一线奥希替尼治疗表皮生长因子受体突变且共存低等位基因分数Thr790Met的非小细胞肺癌患者
AZENT研究(NCT02841579)是一项多中心、单臂、开放标签IIa期研究,评估一线奥希替尼80 mg每日一次治疗EGFR突变阳性晚期NSCLC且共存低等位基因分数Thr790Met患者的疗效与安全性。22例患者中客观缓解率为77.3%,疾病控制率为86.4%,中位无进展生存期为23.1个月,中位总生存期为28.4个月。因奥希替尼在试验期间获批一线适应症,II期研究提前终止,分析被视为探索性。
要点
- 一线奥希替尼80 mg每日一次在EGFR突变且共存低等位基因分数Thr790Met的晚期NSCLC中客观缓解率达77.3%。
- 中位无进展生存期为23.1个月(95%CI 14.1至NE),中位总生存期为28.4个月(95%CI 25.6至NE)。
- 因奥希替尼试验期间获批一线治疗,II期研究提前终止,分析被视为探索性。
核心结论
- 尽管研究提前终止,一线奥希替尼治疗在EGFR突变且共存低等位基因分数Thr790Met突变的患者中总体中位无进展生存期为23.1个月。
研究设计与样本
- 多中心、单臂、开放标签IIa期研究(AZENT,NCT02841579)。
- 入组22例经中心确认携带EGFR Thr790Met突变的局部晚期或转移性NSCLC患者,每日接受奥希替尼80 mg。
- 主要终点为客观缓解率,次要终点包括疾病控制率、无进展生存期、总生存期和安全性。
- 疗效按实体瘤疗效评价标准1.1版评估;基线、第2周结束时和疾病进展时采集血样进行下一代测序分析。
- 因奥希替尼在试验期间获批一线治疗,II期研究提前终止,分析被视为探索性。
主要发现
- 22例患者入组并接受奥希替尼,全部22例纳入疗效和安全性分析;数据截止时10例(50%)仍在治疗中。
- 中位随访时间为24.4个月(四分位距12.9至26.0)。
- 客观缓解率为77.3%(17/22,95%CI 54.6至89.3)。
- 疾病控制率为86.4%(19/22,95%CI 65.1至97.1)。
- 中位无进展生存期为23.1个月(95%CI 14.1至NE),中位总生存期为28.4个月(95%CI 25.6至NE)。
局限性
- 因奥希替尼在试验期间获批一线治疗,II期研究提前终止,分析被视为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM OF THE STUDY: The AZENT (NCT02841579) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR)mutation-positive advanced non-small-cell lung cancer (NSCLC) and with a coexisting low allelic fraction of Thr790Met. METHODS: In this multicentre, single-arm, open-label, phase IIa study, patients with locally advanced or metastatic NSCLC harbouring centrally confirmedEGFR Thr790Met mutation received 80 mg osimertinib daily. The primary end-point was objective response rate (ORR). The secondary end-points included disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety. Efficacy was assessed as per Response Evaluation Criteria in Solid Tumours, version 1.1. Blood samples collected at baseline, end of week 2 and disease progression were analysed using next-generation sequencing. As osimertinib was approved as a first-line therapy during the trial, this led to early termination of phase II; thus, analysis is considered exploratory. RESULTS: Twenty-two patients were enrolled and received osimertinib. All 22 patients were included in the efficacy and safety analysis. At the data cutoff, 10 (50%) patients remained on treatment. The median duration of follow-up was 24.4 months (interquartile range 12.9 to 26.0). The ORR was 77.3% (17/22 [95% confidence interval {CI} 54.6 to 89.3]). The DCR was 86.4% (19/22, [95% CI 65.1 to 97.1]). The median PFS was 23.1 months (95% CI 14.1 to NE). The median OS was 28·4 months (95% CI 25.6 to NE). CONCLUSION: Despite early study termination, osimertinib first-line therapy yields an overall PFS of 23.1 months in EGFR-mutant patients harbouring a coexisting low allelic fraction of EGFR Thr790Met mutation.
引用
- Majem M, Sullivan I, Viteri S, et al. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. Eur J Cancer. 2021. PMID: 34763195. doi:10.1016/j.ejca.2021.09.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。